Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 337 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Current regimen Clear all
Completed Phase 2Phase 3 Interventional Results available

Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen

NCT02285114
View directory record Official record
Conditions
HIV-1
Interventions
F/TAF, 3rd ARV agent, Boosted PIs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
1 Month to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Not applicable Interventional Results available

Individualized Exercise Oncology Program for Newly Diagnosed Breast Cancer Patients

NCT04106609
View directory record Official record
Conditions
Breast Cancer
Interventions
Supervised, individualized exercise oncology program, Current standard of care
Other
Lead sponsor
Karen Wonders
Other
Eligibility
30 Years to 80 Years · Female only
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 19, 2026, 5:29 PM EDT
Recruiting Not applicable Interventional

Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy

NCT07095998
View directory record Official record
Conditions
Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathy, Neurotoxicity Syndromes, Neuropathy
Interventions
Threshold Tracking Nerve Conduction Studies
Diagnostic Test
Lead sponsor
Ka-Wai Ho
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

NCT02065570
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

NCT01532648
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Budesonide MMX®, Placebo, 5-ASA
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
39
States / cities
Anaheim, California • Lakewood, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects

NCT00529243
View directory record Official record
Conditions
HIV Infections
Interventions
raltegravir
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Anaheim, California • Hayward, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Islet Transplantation Using Abatacept

NCT00276250
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Efalizumab, Abatacept, Belatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

NCT05002231
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
Losmapimod 15 mg oral tablet, Losmapimod two 7.5 mg oral tablets, Losmapimod one 15 mg oral tablet
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 19, 2026, 5:29 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Transcendental Meditation in Veterans and First Responders With PTSD

NCT05645042
View directory record Official record
Conditions
PTSD
Interventions
Transcendental Meditation (TM), Present Centered Therapy (PCT)
Behavioral
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 19, 2026, 5:29 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne

NCT04582383
View directory record Official record
Conditions
Acne
Interventions
Spironolactone, Doxycycline Hyclate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
16 Years to 40 Years · Female only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
18
States / cities
Fort Smith, Arkansas • San Francisco, California • Sherman Oaks, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 19, 2026, 5:29 PM EDT
Recruiting Phase 2 Interventional

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

NCT07493538
View directory record Official record
Conditions
AML, MDS, Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Treosulfan, Fludarabine, Total Body Irradiation, Tacrolimus, Mycophenolate Mofetil, Cyclophosphamid, Stem Cell Infusion
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
2 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

NCT03663335
View directory record Official record
Conditions
Kidney Transplantation
Interventions
CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 19, 2026, 5:29 PM EDT
Terminated Not applicable Interventional

Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit

NCT04278690
View directory record Official record
Conditions
Medication Administered in Error
Interventions
HELPix, HELPix+Tech
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 5:29 PM EDT
Completed No phase listed Observational

Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors

NCT01987726
View directory record Official record
Conditions
Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Breast Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
cytology specimen collection procedure, laboratory biomarker analysis
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 19, 2026, 5:29 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

NCT07285460
View directory record Official record
Conditions
Hemophilia
Interventions
Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
1 Year to 11 Years · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • Torrance, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Not applicable Interventional Results available

Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP)

NCT01143766
View directory record Official record
Conditions
Conscious Sedation
Interventions
Gabapentin, Standard sedation regimen
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 19, 2026, 5:29 PM EDT
Recruiting Phase 2 Interventional

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

NCT06115135
View directory record Official record
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions
Venetoclax
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
West Hollywood, California • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Not applicable Interventional

Effects of Multicomponent Training in Older Adults

NCT06094413
View directory record Official record
Conditions
Sarcopenia
Interventions
Multicomponent Training Intervention
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 19, 2026, 5:29 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal Neuroblastoma

NCT01440283
View directory record Official record
Conditions
Abdominal Neuroblastoma
Interventions
Intensity Modulated Radiation Therapy (IMRT)
Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Months to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Pain Management Techniques for Fibromyalgia

NCT00086060
View directory record Official record
Conditions
Fibromyalgia
Interventions
Exercise regimen, Relaxation training, Standard Care
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 10, 2011 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

NCT02422797
View directory record Official record
Conditions
HIV Infections
Interventions
DTG 50 mg, RPV 25 mg, CAR
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
13
States / cities
Bakersfield, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Not applicable Interventional

A Pilot Study Examining the Efficacy of Biomodulator Treatment for Chronic Low Back Pain

NCT02707094
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Biomodulator, Usual Care (Medication + Exercise)
Device · Other
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 62 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 2 Interventional

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

NCT03637556
View directory record Official record
Conditions
Thalassemia Major
Interventions
DST-0509, Jadenu, Exjade
Drug
Lead sponsor
DisperSol Technologies, LLC
Industry
Eligibility
8 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Electrical Stimulus Therapy for Chronic Phantom Limb Pain

NCT03030079
View directory record Official record
Conditions
Phantom Limb Pain
Interventions
Experimental Electrical Stimulation Regimen
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 19, 2026, 5:29 PM EDT